Floatz logo

cgt4255

Advanced Solid Tumor, Adult

Cogent Biosciences, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced Solid Tumor, Adult cohort.

Asset / SponsorPhaseRating
Camonsertib
Repare Therapeutics
Phase 1/2CC
Vobramitamab Duocarmazine
MacroGenics
Phase 1/2C

Same molecule, other indications

cgt4255 is also rated in:

HER2 positive breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
ERBB2 Gene AmplificationDormant
CC
Indicative ·
43 / 100
View asset →
HER2 OverexpressionDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →